No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

This achievement follows Bahrain’s landmark decision on 2 December 2023 to become the second country globally and the first ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Bahrain has achieved a medical milestone by successfully treating a patient with sickle cell disease (SCD) using ...

The Bahrain Oncology Centre (BOC) has made medical history by successfully treating a sickle cell disease (SCD) patient using ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

The global Gene Editing Market was valued at $5.1 billion in 2022 and is projected to reach $16.2 billion by 2030, growing at ...

Evercore ISI analyst Liisa Bayko raised the price target for CRISPR Therapeutics from $60.00 to $99.00. Bayko's optimism is driven by upcoming catalysts that could mark a new chapter for the company.

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.